Cochrane
Library

Cochrane Database of Systematic Reviews

Surgical cytoreduction for recurrent epithelial ovarian cancer (Review)

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K.
Surgical cytoreduction for recurrent epithelial ovarian cancer.
Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD008765.
DOI: [10.1002/14651858.CD008765.pub3](https://doi.org/10.1002/14651858.CD008765.pub3).

www.cochranelibrary.com

TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	3
OBJECTIVES	3
METHODS	4
RESULTS	7
Figure 1.	8
Figure 2.	9
Figure 3.	11
DISCUSSION	11
AUTHORS' CONCLUSIONS	13
ACKNOWLEDGEMENTS	13
REFERENCES	14
CHARACTERISTICS OF STUDIES	17
DATA AND ANALYSES	37
Analysis 1.1. Comparison 1 Residual disease (RD) > 0 cm versus microscopic disease, Outcome 1 Overall survival.	37
Analysis 2.1. Comparison 2 Residual disease (RD) ≤ 1 cm versus microscopic disease, Outcome 1 Overall survival.	37
Analysis 3.1. Comparison 3 Residual disease (RD) ≤ 2 cm versus microscopic disease, Outcome 1 Overall survival.	38
Analysis 4.1. Comparison 4 Residual disease (RD) > 1 cm versus microscopic disease, Outcome 1 Overall survival.	38
Analysis 5.1. Comparison 5 Residual disease (RD) > 2 cm versus microscopic disease, Outcome 1 Overall survival.	39
Analysis 6.1. Comparison 6 Residual disease (RD) > 1 cm versus RD ≤ 1 cm, Outcome 1 Overall survival.	39
Analysis 7.1. Comparison 7 Overall survival, Outcome 1 Overall survival.	40
APPENDICES	41
WHAT'S NEW	43
HISTORY	43
CONTRIBUTIONS OF AUTHORS	43
DECLARATIONS OF INTEREST	44
SOURCES OF SUPPORT	44
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	44
INDEX TERMS	45

[Intervention Review]

Surgical cytoreduction for recurrent epithelial ovarian cancer

Thuria Al Rawahi¹, Alberto D Lopes², Robert E Bristow³, Andrew Bryant⁴, Ahmed Elattar⁵, Supratik Chattopadhyay⁶, Khadra Galaal²

¹Department of Obstetrics and Gynaecology, The Royal Hospital, Seeb, Oman. ²Gynaecological Oncology, Princess Alexandra Wing, Royal Cornwall Hospital, Truro, UK. ³Division of Gynecologic Oncology, University of California - Irvine, Medical Center, Orange, CA, USA. ⁴Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK. ⁵City Hospital & Birmingham Treatment Centre, Birmingham, UK. ⁶Gynaecological Oncology, St James's University Hospital, Leeds, UK

Contact: Khadra Galaal, Gynaecological Oncology, Princess Alexandra Wing, Royal Cornwall Hospital, Truro, Cornwall, TR1 3LJ, UK. k.galaal@nhs.net, khadragalaal@yahoo.co.uk.

Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group.

Publication status and date: Edited (no change to conclusions), published in Issue 9, 2016.

Citation: Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 2. Art. No.: CD008765. DOI: [10.1002/14651858.CD008765.pub3](https://doi.org/10.1002/14651858.CD008765.pub3).

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

The standard management of primary ovarian cancer is optimal cytoreductive surgery followed by platinum-based chemotherapy. Most women with primary ovarian cancer achieve remission on this combination therapy. For women achieving clinical remission after completion of initial treatment, most (60%) with advanced epithelial ovarian cancer will ultimately develop recurrent disease. However, the standard treatment of women with recurrent ovarian cancer remains poorly defined. Surgery for recurrent ovarian cancer has been suggested to be associated with increased overall survival.

Objectives

To evaluate the effectiveness and safety of optimal secondary cytoreductive surgery for women with recurrent epithelial ovarian cancer. To assess the impact of various residual tumour sizes, over a range between 0 cm and 2 cm, on overall survival.

Search methods

We searched the Cochrane Gynaecological Cancer Group Trials Register, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) up to December 2012. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. For databases other than MEDLINE, the search strategy has been adapted accordingly.

Selection criteria

Retrospective data on residual disease, or data from randomised controlled trials (RCTs) or prospective/retrospective observational studies that included a multivariate analysis of 50 or more adult women with recurrent epithelial ovarian cancer, who underwent secondary cytoreductive surgery with adjuvant chemotherapy. We only included studies that defined optimal cytoreduction as surgery leading to residual tumours with a maximum diameter of any threshold up to 2 cm.

Data collection and analysis

Two review authors (KG, TA) independently abstracted data and assessed risk of bias. Where possible the data were synthesised in a meta-analysis.

Main results

There were no RCTs; however, we found nine non-randomised studies that reported on 1194 women with comparison of residual disease after secondary cytoreduction using a multivariate analysis that met our inclusion criteria. These retrospective and prospective studies assessed survival after secondary cytoreductive surgery in women with recurrent epithelial ovarian cancer.

Meta- and single-study analyses show the prognostic importance of complete cytoreduction to microscopic disease, since overall survival was significantly prolonged in these groups of women (most studies showed a large statistically significant greater risk of death in all residual disease groups compared to microscopic disease).

Recurrence-free survival was not reported in any of the studies. All of the studies included at least 50 women and used statistical adjustment for important prognostic factors. One study compared sub-optimal (> 1 cm) versus optimal (< 1 cm) cytoreduction and demonstrated benefit to achieving cytoreduction to less than 1 cm, if microscopic disease could not be achieved (hazard ratio (HR) 3.51, 95% CI 1.84 to 6.70). Similarly, one study found that women whose tumour had been cytoreduced to less than 0.5 cm had less risk of death compared to those with residual disease greater than 0.5 cm after surgery (HR not reported; P value < 0.001).

There is high risk of bias due to the non-randomised nature of these studies, where, despite statistical adjustment for important prognostic factors, selection is based on retrospective achievability of cytoreduction, not an intention to treat, and so a degree of bias is inevitable.

Adverse events, quality of life and cost-effectiveness were not reported in any of the studies.

Authors' conclusions

In women with platinum-sensitive recurrent ovarian cancer, ability to achieve surgery with complete cytoreduction (no visible residual disease) is associated with significant improvement in overall survival. However, in the absence of RCT evidence, it is not clear whether this is solely due to surgical effect or due to tumour biology. Indirect evidence would support surgery to achieve complete cytoreduction in selected women. The risks of major surgery need to be carefully balanced against potential benefits on a case-by-case basis.

PLAIN LANGUAGE SUMMARY

Surgery to remove tumour so that it is not visible with the naked eye prolongs survival in women with recurrent epithelial ovarian cancer

Epithelial ovarian cancer is a disease in which malignant cells form in the tissue covering the ovary. It accounts for about 90% of ovarian cancers; the remaining 10% arise from germ cells or the sex cords and stroma of the ovary. Women with epithelial ovarian cancer that has returned after primary treatment (recurrent disease) may need secondary surgery to remove all or part of the cancer. When ovarian cancer recurs after more than six months it is considered suitable for further treatment with platinum chemotherapy (platinum sensitive).

The results of this review suggest that surgery may be associated with improved outcomes in terms of prolonging life in some women (platinum-sensitive disease). In particular, surgery removing all visible disease is associated with a significant improvement in survival, although this may be due to the cancer biology facilitating surgery, rather than the surgery itself. We conclude from the current evidence that surgery with the aim of removing all visible disease should be considered in women with recurrent ovarian cancer on an individual basis. However, the data are limited to non-randomised studies with a median age of women in their 50s and early 60s, which may not be representative of all women with ovarian cancer. The risks of major surgery need to be carefully balanced against potential benefits on a case-by-case basis.

BACKGROUND

Description of the condition

Ovarian cancer is the sixth most common cancer among women. Worldwide there are more than 200,000 new cases of ovarian cancer each year, accounting for around 4% of all cancers diagnosed in women with approximately 6.6 new cases per 100,000 women per year (GLOBOCAN 2008; Hannibal 2008). A woman's risk of developing ovarian cancer by age 75 years varies between countries, ranging from 0.5% to 1.6% (IARC 2002). In Europe, just over one-third of women with ovarian cancer are alive five years after diagnosis (EUROCARE 2003). The poor survival associated with ovarian cancer is largely because most women are diagnosed when the cancer is already at an advanced stage (Jemal 2008).

Epithelial ovarian cancer accounts for about 90% of ovarian cancers, the remaining 10% arise from germ cells or the sex cords and stroma of the ovary. Approximately 75% to 80% of epithelial ovarian cancers are of serous histological type, less common are mucinous, endometrioid, clear cell, Brenner and undifferentiated cancers (Scully 1998).

Most women with ovarian cancer have widespread disease at presentation (Federation of Gynaecology and Obstetrics (FIGO) stage III to IV) (Appendix 1). This may be due to relatively early spread and implantation of high-grade serous cancers to the rest of the peritoneal cavity. In addition, presenting symptoms such as abdominal pain and swelling, gastrointestinal symptoms, and pelvic pain, are often unrecognised leading to possible delay in diagnosis (Goff 2000; Smith 2005).

Description of the intervention

Surgery is the first step in the initial diagnosis and staging of ovarian cancer. The standard management of primary ovarian cancer is optimal cytoreductive surgery (usually defined as reduction of residual disease to less than 1 to 2 cm) followed by platinum-based chemotherapy (Bristow 2002; Delgado 1984; Hacker 1983; Hoskins 1994; Piver 1988). In a randomised trial, women with stage IIIC and IV ovarian cancer randomised to neoadjuvant chemotherapy followed by interval cytoreduction had similar survival compared to women randomised to primary cytoreductive surgery followed by chemotherapy (Vergote 2011). The postoperative complications and mortality rates were lower after interval cytoreduction. The most important independent prognostic factor for overall survival (OS) was complete cytoreduction (no residual tumour) after primary or interval surgery (Vergote 2011).

Most women with primary ovarian cancer achieve remission on this combination therapy. The theoretical benefit from cytoreductive surgery relates to removing large tumour volumes that have a decreased growth fraction and poor blood supply, thereby improving the efficacy of chemotherapeutic agents (Boente 1998). For women achieving clinical remission after completion of initial treatment, most (60%) with advanced epithelial ovarian cancer will ultimately develop recurrent disease within five years (Burke 1994).

Secondary cytoreductive surgery is defined as surgery after completion of the primary treatment, and a period of remission, to further debulk the recurrent tumour. Surgery in the recurrent setting aims at prolongation of survival and is not curative. The apparent benefits of optimal primary surgery in advanced ovarian

cancer have prompted investigations into the role of secondary surgery for recurrent disease after a period of clinical remission. These studies, which included a heterogeneous group of women, suggested that secondary cytoreductive surgery may have survival benefits in selected women (Gungor 2005; Tebes 2007). In addition, various chemotherapeutic agents including platinum are often given after secondary cytoreductive surgery.

One meta-analysis on surgery for recurrent ovarian cancer complete cytoreductive surgery was shown to be independently associated with increased overall post-recurrence survival time (Bristow 2009).

A number of chemotherapeutic agents are active in recurrent ovarian cancer including a combination of platinum and paclitaxel (Gonzalez-Martin 2003; Parmar 2003). Other chemotherapeutic agents with activity in recurrent ovarian cancer include: topotecan, etoposide, doxycycline and bevacizumab (Avastin) (Bookman 1998; Markman 2004). Newer chemotherapeutic agents have shown activity in recurrent ovarian cancer and response rates of 20% to 30% have been described (Ozols 2005; Wright 2006). These chemotherapeutic agents are sometimes given within research protocols. Response to these agents is often short-lived and they have a significant toxicity profile (Munkarah 2004).

Why it is important to do this review

The standard treatment of women with recurrent ovarian cancer remains poorly defined. Surgical debulking (cytoreduction) may be associated with improved outcomes in terms of survival in selected cases (platinum-sensitive disease), with no residual disease emerging as the 'best' surgical objective. A systematic review and meta-analysis is essential to make a reliable evaluation of the potential benefits and risks of surgical cytoreduction with or without adjuvant chemotherapy in recurrent ovarian cancer. One systematic review on cytoreductive surgery for recurrent ovarian cancer suggested that complete cytoreduction confers survival benefit (Bristow 2009). A Cochrane review (Galaal 2010) did not identify any studies that compared the effectiveness and safety of secondary surgical cytoreduction to chemotherapy alone for women with recurrent epithelial ovarian cancer. Therefore it is important to review the current evidence whether secondary cytoreductive surgery with or without adjuvant is associated with a survival benefit in women with recurrent ovarian cancer. In addition, it is important to evaluate the harms of surgery and chemotherapy in a non-curative setting, so that women and their clinicians can adequately weigh the pros and cons of proposed treatment options.

OBJECTIVES

1. To evaluate the effectiveness and safety of optimal secondary cytoreductive surgery for women with recurrent epithelial ovarian cancer.
2. To assess the impact of various residual tumour sizes, over a range between 0 cm and 2 cm, on OS.

METHODS

Criteria for considering studies for this review

Types of studies

There are no randomised controlled trials (RCTs) assigning women to sub-optimal cytoreductive surgery versus complete cytoreduction as yet. Therefore this review was based on retrospective and prospective non-randomised data. We only included data from prospective and retrospective cohort studies and unselected case series of 50 or more women that included concurrent comparison groups. Data collected from RCTs were retrospective as groups of women were randomised to surgery, where residual disease was categorised based on microscopic (no visible disease), optimal and sub-optimal disease without taking into account the method of surgical intervention.

Case-control studies, studies that did not have concurrent comparison groups and case series of fewer than 50 women were excluded.

In order to minimise selection bias, we included only studies that used statistical adjustment for baseline case mix using multivariable analyses (e.g. age, stage, grade, etc.).

Types of participants

- Adult women (over age 18 years) diagnosed with platinum-sensitive recurrent epithelial ovarian cancer who received secondary cytoreductive surgery and adjuvant platinum-based chemotherapy.
- Women with other concurrent malignancies were excluded.

Types of interventions

- Intervention: secondary optimal cytoreductive surgery followed by adjuvant platinum-based chemotherapy. We only included studies that defined optimal cytoreduction as surgery leading to residual tumours with a maximum diameter of any threshold up to 2 cm.
- Comparison: women who had secondary surgery resulting in residual disease, which did not meet the criteria specified in the study as 'optimal', followed by adjuvant platinum-based chemotherapy.

Types of outcome measures

Primary outcomes

Primary outcomes

1. OS: survival until death from all causes. Survival had been assessed from the time when women were diagnosed with recurrent disease.

Secondary outcomes

1. Progression-free survival (PFS).
2. Quality of life (QoL), measured using a scale that has been validated through reporting of norms in a peer-reviewed publication.
3. Adverse events (CTCAE 2006):
 - a. direct surgical morbidity (e.g. death within 30 days; injury to bladder, ureter, blood vessels, small bowel or colon),

presence and complications of adhesions, febrile morbidity, intestinal obstruction, haematoma, local infection);

- b. surgically related systemic morbidity (chest infection, thromboembolic events (deep vein thrombosis and pulmonary embolism), cardiac events (cardiac ischaemias and cardiac failure), cerebrovascular accident);
- c. recovery: delayed discharge, unscheduled re-admission;
- d. chemotherapy toxicity;
- e. other.

Grades of chemotherapeutic toxicity were extracted and grouped as:

- a. haematological (leukopenia, anaemia, thrombocytopenia, neutropenia, haemorrhage);
- b. gastrointestinal (nausea, vomiting, anorexia, diarrhoea, liver, proctitis);
- c. genitourinary;
- d. skin (stomatitis, mucositis, alopecia, allergy);
- e. neurological (peripheral and central);
- f. pulmonary.

Search methods for identification of studies

Papers in all languages were sought and translations carried out when necessary.

Electronic searches

See: [Cochrane Gynaecological Cancer Group](#) methods used in reviews.

The following electronic databases were searched:

- the Cochrane Gynaecological Cancer Collaborative Review Group's Trial Register;
- the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 11, 2012;
- MEDLINE to December 2012;
- EMBASE to December 2012

The MEDLINE, EMBASE and CENTRAL search strategy based on terms related to the review topic are presented in [Appendix 2](#), [Appendix 3](#) and [Appendix 4](#), respectively.

For databases other than MEDLINE, the search strategy has been adapted accordingly.

All relevant articles found had been identified on PubMed and using the 'related articles' feature, a further search had been carried out for newly published articles.

Searching other resources

Unpublished and Grey literature

We searched Metaregister, Physicians Data Query, www.controlled-trials.com/rct, www.clinicaltrials.gov, www.cancer.gov/clinicaltrials and Gynaecologic Oncologists of Canada (<http://www.g-o-c.org>) for ongoing trials.

Handsearching

We handsearched the following reports of conferences:

- Gynecologic Oncology (Annual Meeting of the American Society of Gynecologic Oncologists);
- Biennial Meeting of the International Gynecologic Cancer Society (IGCS), and the European Society of Gynaecological Oncology (ESGO);
- *British Journal of Cancer*;
- British Cancer Research Meeting;
- Annual Meeting of European Society of Medical Oncology (ESMO);
- Annual Meeting of the American Society of Clinical Oncology (ASCO);
- BioMed (open text publisher); American Association for Cancer Research (AACR) conferences.

We searched the *Journal of Ovarian Research* (www.ovarianresearch.com/home/).

Reference lists and correspondence

We checked the citation lists of included studies and contacted experts in the field to identify further reports of studies.

Data collection and analysis

Selection of studies

We downloaded all titles and abstracts retrieved by electronic searching to the reference management database Endnote X5.0.1, removed duplicates and two review authors (KG, TA) examined the remaining references independently. We excluded those studies that clearly did not meet the inclusion criteria and obtained copies of the full text of potentially relevant references. Two review authors (KG, TA) assessed the eligibility of retrieved papers independently and resolved disagreements by discussion between two review authors (KG and TA) or by appeal to a third review author (AB). We documented reasons for exclusion (see [Characteristics of excluded studies](#)).

Data extraction and management

We extracted data for included studies, as recommended in Chapter 7 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2008](#)). This included data on the following:

- author, year of publication and journal citation (including language);
- country;
- setting;
- inclusion and exclusion criteria;
- study design, methodology;
- study population:
 - total number enrolled;
 - participant characteristics;
 - age;
 - co-morbidities;

- ovarian cancer details at diagnosis:
 - FIGO stage;
 - histological cell type;
 - tumour grade;
 - extent of disease;
 - disease-free interval;
 - number of recurrences;
- total number of intervention groups;
- intervention details:
 - details of secondary cytoreductive surgery
 - type of surgeon (gynae-oncologist, gynaecologist, general surgeon);
 - experience of surgeon;
 - details of chemotherapy:
 - dose;
 - cycle length;
 - combination;
 - details of best supportive care;
- risk of bias in study (see below);
- duration of follow-up;
- outcomes - OS, PFS, QoL, patient satisfaction and adverse events:
 - for each outcome: outcome definition (with diagnostic criteria if relevant);
 - unit of measurement (if relevant);
 - for scales: upper and lower limits, and whether high or low score was good;
 - results: number of participants allocated to each intervention group;
 - for each outcome of interest: sample size; missing participants.

Data on outcomes were extracted as below

- For time-to-event (OS) data, we extracted the log of the hazard ratio [log(HR)] and its standard error from trial reports; if these are not reported, we attempted to estimate them from other reported statistics using the methods of [Parmar 1998](#).

Where possible, all data extracted were those relevant to an intention-to-treat (ITT) analysis, in which participants are analysed in groups to which they were assigned.

The time points at which outcomes were collected and reported had been noted.

Two review authors (KG, TA) independently abstracted data onto a data abstraction form specially designed for the review. The review authors resolved differences of opinion by discussion or by appeal to a third review author (AB) when necessary.

Assessment of risk of bias in included studies

The risk of bias in included RCTs was assessed using the following questions and criteria.

Sequence generation

Was the allocation sequence adequately generated?

- This item was scored as being 'at high risk of bias' as given the scope of the review, randomisation within a study was not feasible.

Allocation concealment

Was allocation adequately concealed?

- This item was scored as being 'at high risk of bias' as given the scope of the review, concealment of the allocation within a study was not applicable.

Blinding

Assessment of blinding had been restricted to blinding of outcome assessors, since it is generally not possible to blind participants and treatment providers to surgical interventions.

Was knowledge of the allocated interventions adequately prevented during the study?

- Yes.
- No.
- Unclear.

Incomplete reporting of outcome data

We recorded the proportion of participants whose outcomes were not reported at the end of the study; we noted if loss to follow-up was not reported.

Were incomplete outcome data adequately addressed?

- Yes, if fewer than 20% of women were lost to follow-up and reasons for loss to follow-up were similar in both treatment arms.
- No, if more than 20% of women were lost to follow-up or reasons for loss to follow-up differed between treatment arms.
- Unclear if loss to follow-up was not reported.

Selective reporting of outcomes

Are reports of the study free of suggestion of selective outcome reporting?

- Yes, for example, if review reports all outcomes specified in the protocol.
- No.
- Unclear.

Other potential threats to validity

Was the study apparently free of other problems that could put it at a high risk of bias?

- Yes.
- No.
- Unclear.

The risk of bias in non-randomised studies was assessed in accordance with four additional criteria.

Cohort selection

1. Was the cohort studied representative of women with recurrent epithelial ovarian cancer?
 - a. Yes, if representative of women with recurrent epithelial ovarian cancer.
 - b. No, if group of women was selected.
 - c. Unclear, if selection of group was not described.

Comparability of treatment groups

1. Were there no differences between the two groups or differences controlled for, in particular with reference to age, FIGO stage, disease-free interval, histology, type and experience of surgeon, number of recurrences and dose and duration of chemotherapy?
 - a. Yes, if at least three of these characteristics were reported and any reported differences were controlled for.
 - b. No, if the two groups differed and differences were not controlled for.
 - c. Unclear, if fewer than three of these characteristics were reported, even if there were no other differences between the groups, and other characteristics had been controlled for.

The risk of bias tool had been applied independently by two review authors (KG, TA) and differences resolved by discussion or by appeal to a third review author (AB). Results had been presented in both a 'Risk of bias' graph and a 'Risk of bias' summary. Results of meta-analyses had been interpreted in light of the findings with respect to risk of bias.

Measures of treatment effect

We used the following measures of the effect of treatment.

- For time to event data, we used the HR to compare the risk of death or disease progression in the treatment group with that in the control group.

Dealing with missing data

We did not impute missing outcome data for the primary outcome.

Assessment of heterogeneity

Heterogeneity between studies was assessed by visual inspection of forest plots, by estimation of the percentage heterogeneity between trials that cannot be ascribed to sampling variation (Higgins 2003) and by a formal statistical test of the significance of the heterogeneity (Deeks 2001). If there is evidence of substantial heterogeneity, the possible reasons for this had been investigated and reported.

Data synthesis

If sufficient, clinically similar studies were available their results were pooled in meta-analyses. Adjusted summary statistics were used.

- For time-to-event data, HRs had been pooled using the generic inverse variance facility of RevMan 5 (RevMan 2011).

Random-effects models with inverse variance weighting were used for all meta-analyses (DerSimonian 1986).

RESULTS

Description of studies

Results of the search

The search strategy identified 522 unique references. The title and abstract screening of these references identified 33 studies as potentially eligible for the review. The full-text screening of the 33 studies excluded 24 for the reasons described in the table [Characteristics of excluded studies](#). The remaining nine studies met our inclusion criteria and are described in the table [Characteristics of included studies](#).

Searches of the grey literature did not identify any additional relevant studies.

Included studies

The nine included studies ([Ayhan 2006](#); [Chi 2006](#); [Eisenkop 2000](#); [Harter 2006](#); [Oksefjell 2009](#); [Salani 2007](#); [Scarabelli 2001](#); [TIAN 2010](#); [Zang 2000](#)) assessed a total of 1194 women.

The number of women included in all studies varied from 267 women in the [Harter 2006](#) study to 60 women in the [Zang 2000](#) study.

Design

Retrospective studies comprised seven out of the nine included studies ([Ayhan 2006](#); [Chi 2006](#); [Harter 2006](#); [Oksefjell 2009](#); [Salani 2007](#); [TIAN 2010](#); [Zang 2000](#)). Two studies were prospective cohort studies ([Eisenkop 2000](#); [Scarabelli 2001](#)).

Participant characteristics

Women diagnosed with recurrent epithelial ovarian cancer at least of six months post primary treatment. The median age reported for women with recurrent epithelial ovarian cancer varied between 49 and 75 years.

Intervention details

SCR surgery for women with platinum-sensitive recurrent epithelial ovarian cancer. All studies commented on the surgery to include resection of the recurrent tumour, as well as resection of viscera, with the aim of removing all visible disease, if possible. In these studies the majority (87-100%) of women received postoperative chemotherapy with most receiving platinum-based chemotherapy.

Outcomes

The median duration of follow-up varied from 26 months ([TIAN 2010](#)) to 36.9 months ([Chi 2006](#)). The duration of follow-up was not reported in four studies ([Eisenkop 2000](#); [Harter 2006](#); [Oksefjell 2009](#); [Zang 2000](#)).

All nine studies reported OS; all of which used appropriate statistical techniques (HRs to correctly allow for censoring), but three studies ([Chi 2006](#); [Eisenkop 2000](#); [Salani 2007](#)) did not report sufficient estimates for OS to include in forest plots or meta-analyses. These studies reported either only P values from the Cox model or the point estimate of the HR with the Cox P value. Prognostic factors were adjusted for in the analysis of survival outcomes in all nine included studies using Cox regression.

The HR in the [Ayhan 2006](#) study was adjusted for: residual disease; disease-free interval; outcome of primary debulking surgery; chemotherapy before secondary cytoreduction; tumour histology; number of recurrent sites; median survival of women with only one recurrence and women with two or more recurrences; interval from appearance of recurrent disease to secondary cytoreduction and maximal diameter of the recurrent disease; age; stage and grade.

The HR in the [Chi 2006](#) study was adjusted for: residual disease after secondary cytoreduction; FIGO stage; tumour histology; tumour grade; carcinomatosis at first debulking; residual disease after first debulking; second-look findings; method of detection; site of largest tumour; ascites; number of sites; age; CA-125 and disease-free interval.

The HR in the [Eisenkop 2000](#) study was adjusted for: residual disease after secondary cytoreduction; age; Gynecologic Oncology Group (GOG) performance status; tumour grade; histology; ascites (presence or absence); location of largest recurrent tumour; subspecialty training of physicians involved at primary cytoreduction; number or specific types of procedures performed at secondary cytoreduction; symptoms (presence or absence); physical findings; preoperative radiographic (computed tomography (CT) or magnetic resonance imaging (MRI)) findings; disease-free interval; administration of chemotherapy prior to surgery; and the largest size of recurrent tumour.

The HR in the [Harter 2006](#) study was adjusted for: residual disease after secondary cytoreduction; residual disease after secondary cytoreduction; Eastern Cooperative Oncology Group (ECOG); ascites; localisation of recurrence in preoperative diagnosis in pelvis; platinum-based chemotherapy after surgery for recurrence and treatment-free interval (< six months vs. six to 12 months and < six months vs. > 12 months).

The HR in the [Oksefjell 2009](#) study was adjusted for: residual disease after secondary cytoreduction; FIGO stage; degree of differentiation; residual disease after primary operation; chemotherapy and age (years) at relapse; treatment group and treatment-free interval.

The HR in the [Salani 2007](#) study was adjusted for: residual disease after secondary cytoreduction; age; second-look outcome (positive and negative); elevated CA-125; histology; grade; ascites; greatest dimension of recurrence; number of recurrence sites (imaging and actual) and diagnosis-to-recurrence interval (≥ 18 months).

The HR in the [Scarabelli 2001](#) study was adjusted for: residual disease after secondary cytoreduction; residual tumour after primary surgery; recurrence-free interval; prior chemotherapy combination from primary surgery; lymph node status and age.

The HR in the [TIAN 2010](#) study was adjusted for: residual disease after secondary cytoreduction; FIGO stage; histology; grade; primary cytoreduction; median PFS; ascites; recurrent lesions; maximum diameter of the largest recurrent site; intestinal resection and chemotherapy after secondary cytoreductive surgery.

The HR in the [Zang 2000](#) study was adjusted for: residual disease after secondary cytoreduction; residual disease after secondary cytoreduction; progression-free interval and refractory ascites (ascites presenting in company with recurrent disease).

For the distribution of these factors at baseline for each study by treatment arm see the table [Characteristics of included studies](#).

Adverse events and QoL were not reported by treatment arm or to a satisfactory level in any of the studies.

Excluded studies

Twenty-four references were excluded, after obtaining the full text, for the following primary reasons.

- Seventeen studies (Benedetti 2006; Berek 1983; Bristow 2003; Eisenkop 1995; Gadducci 2000; Gronlund 2005; Gungor 2005; Helm 2007; Landoni 1998; Matsumoto 2006; Morris 1989; Munkarah 2001; Park 2006; Tay 2002; Vaccarello 1995; van der Vange 2000; Zanon 2004) were excluded because the study did not include at least 50 women with recurrent epithelial ovarian cancer.
- Two studies (Tebes 2007; van der Vange 2000) did either not report multivariate analyses or did not include residual disease as a variable.

- Three studies (Goto 2011; Zang 2000a; Zang 2004) did not report survival by residual disease.
- One study (Bristow 2009) had no comparison group.
- One study (Karam 2007) was retrospective study for secondary and tertiary cytoreduction.
- One study (Zang 2003) did not report the results of secondary surgery by residual disease. Instead the authors included the effect of giving the women 'redebunking surgery' (secondary cytoreduction) or secondary chemotherapy in a multivariate Cox regression analysis for OS.

For further details of all the excluded studies see the [Characteristics of excluded studies](#).

Risk of bias in included studies

Although the included studies were a combination of prospective and retrospective studies, the comparison of residual disease was retrospective in nature in all cases and consequently all studies were at high risk of bias as they, at most, only satisfied three of the eight criteria used to assess risk of bias (see [Figure 1](#); [Figure 2](#)).

Figure 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	Representative sample?	Comparability of groups?
Ayhan 2006	⊖	⊖	?	+	?	?	+	+
Chi 2006	⊖	⊖	?	+	?	⊖	+	+
Eisenkop 2000	⊖	⊖	?	+	?	?	+	+
Harter 2006	⊖	⊖	?	+	?	?	+	+
Oksefjell 2009	⊖	⊖	?	+	?	?	+	+
Salani 2007	⊖	⊖	?	+	?	?	+	+
Scarabelli 2001	⊖	⊖	?	+	?	?	+	+
TIAN 2010	⊖	⊖	?	+	?	?	+	+
Zang 2000	⊖	⊖	?	+	?	⊖	+	+

The method of sequence generation and allocation of concealment was not applicable to the studies included in the review, so these individual items were flagged up as being at high risk of bias for all studies. Blinding of the outcome assessor was not reported in any of the studies and it was unclear whether there had been selective reporting of outcomes in all of the studies. There was insufficient

information to make judgement on whether any additional risk factor for bias existed, apart from the [Chi 2006](#) and [Zang 2000](#) studies. In the [Chi 2006](#) study, details of specific information on outcomes of comparable women with recurrent disease, who were managed without secondary cytoreduction, were lacking, while in the [Zang 2000](#) study details of women who received

chemotherapy pre- and post-secondary cytoreductive surgery was not provided. In all included studies women were analysed for OS using appropriate statistical techniques, which were used to account for any censoring. Additionally, all studies appeared to include a representative sample of women with recurrent ovarian cancer that had been cytoreduced via secondary cytoreductive surgery and multivariate analysis was used to adjust for important prognostic factors in a Cox regression model for OS in all studies, making the groups comparable.

Effects of interventions

Meta-analyses of survival are based on HRs that were adjusted for prognostic variables (see [Included studies](#) for full details).

Overall survival (risk of death from all causes)

Residual disease > 0 cm (macroscopic disease; any visible tumour of any size) versus microscopic disease

(See [Analysis 1.1](#)).

Four studies ([Ayhan 2006](#); [Eisenkop 2000](#); [Harter 2006](#); [Salani 2007](#)) reported a comparison of microscopic disease (no visible residual disease) versus macroscopic disease (visible residual disease) in a multivariate analysis, but [Eisenkop 2000](#) did not report a confidence interval or a standard error of the log HR and [Salani 2007](#) only reported the significance probabilities of significant variables in the Cox model. Meta-analysis of two studies ([Ayhan 2006](#); [Harter 2006](#)), assessing 331 participants, found that women with macroscopic disease after secondary cytoreductive surgery had over 2.5 times the risk of death compared to women with only microscopic disease (HR 2.62, 95% CI 1.67 to 4.11; $P < 0.0001$). The percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) was not important ($I^2 = 0\%$).

The [Eisenkop 2000](#) study found that women with no visible disease after secondary cytoreductive surgery had 87% less risk of death compared to women with macroscopic disease (HR 0.13; P value = 0.007). The median survival after complete secondary cytoreduction was 44.4 months versus 19.3 months for sub-optimal cytoreduction (P value = 0.007). The [Salani 2007](#) study found that only three factors were associated independently and significantly with post-recurrence and OS and these included a diagnosis-to-recurrence interval ≥ 18 months ($P = 0.001$), complete cytoreduction after secondary cytoreductive surgery ($P < 0.001$) and the number of recurrence sites (imaging ($P = 0.005$) and actual ($P = 0.06$)). The median survival was 50 months for women with microscopic disease after secondary debulking and 7.2 months for women who had visible residual disease.

Residual disease < 1 cm versus microscopic disease

(See [Analysis 2.1](#)).

Meta-analysis of two studies ([Scarabelli 2001](#); [TIAN 2010](#)), assessing 272 participants, found that women who were optimally debulked (residual disease < 1 cm) after secondary cytoreductive surgery had nearly three times the risk of death compared to women with only microscopic disease (HR 2.91, 95% CI 1.78 to 4.77). The percentage of the variability in effect estimates that is due to heterogeneity rather than chance was not important ($I^2 = 0\%$).

Residual disease < 2 cm versus microscopic disease

(See [Analysis 3.1](#)).

The [Oksefjell 2009](#) study, which assessed 217 participants, found that women who were optimally debulked (residual disease < 2 cm) after secondary cytoreductive surgery had more than twice the risk of death compared to women with only microscopic disease (HR 2.18, 95% CI 1.32 to 3.60). The median survival was 4.5 years in women who had cytoreduction to no residual disease compared to 2.3 years when ≤ 2 cm macroscopic disease was left.

Residual disease > 1 cm versus microscopic disease

(See [Analysis 4.1](#)).

Meta-analysis of two studies ([Scarabelli 2001](#); [TIAN 2010](#)), assessing 217 participants, found that women who were sub-optimally debulked (residual disease > 1 cm) after secondary cytoreductive surgery had nearly seven times the risk of death compared to women with only microscopic disease (HR=6.80, 95% CI: 3.95 to 11.71). The percentage of the variability in effect estimates that is due to heterogeneity rather than chance is not important ($I^2 = 0\%$).

Residual disease > 2 cm versus microscopic disease

(See [Analysis 5.1](#)).

The [Oksefjell 2009](#) study, which assessed 217 participants, found that women who were sub-optimally debulked (residual disease > 2 cm) after secondary cytoreductive surgery had more than seven and a half times the risk of death compared to women with only microscopic disease (HR 7.69, 95% CI 4.62 to 12.80). The median survival was 4.5 years in women who had complete cytoreduction compared to 0.7 years in women left with residual disease > 2 cm.

Residual disease > 0.5 cm versus residual disease < 0.5 cm

The authors of the [Chi 2006](#) study reported estimates for a comparison of residual disease less than 0.5 cm versus more than 0.5 cm in univariate analyses, but only reported the significance probabilities of significant variables in multivariate analyses. They found that only disease-free interval ($P = 0.004$), the number of sites of recurrence ($P = 0.01$) and residual disease after secondary cytoreduction (P value < 0.001) were significant in multivariate analysis. The median survival was 56 months for women who had residual disease that measured ≤ 0.5 cm after secondary debulking and 27 months for women who had residual disease that measured > 0.5 cm.

Residual disease > 1 cm versus residual disease < 1 cm

(See [Analysis 6.1](#)).

The [Zang 2000](#) study, which assessed 106 participants, found that women who were sub-optimally debulked (residual disease > 1 cm) after secondary cytoreductive surgery had around three and a half times the risk of death compared to women who were optimally debulked with residual disease < 1 cm (HR 3.51, 95% CI 1.84 to 6.70). Median survival was 19 months for women who had optimal cytoreduction versus 8 months for women with sub-optimal cytoreduction.

No residual disease (microscopic disease) versus any residual disease

(See Analysis 7.1).

Combining the results from all of the included studies has suggested that there is a significant improvement in the OS when the outcome of cytoreductive surgery is no visible disease (microscopic disease), see Figure 3.

Figure 3. Forest plot of comparison: Overall survival, microscopic disease vs. any residual disease (RD).

DISCUSSION

Summary of main results

We found two prospective and seven retrospective studies that included a multivariate analysis that met our inclusion criteria, although the comparison of residual disease was retrospective in nature in all cases. These studies assessed survival after secondary cytoreductive surgery in women with recurrent epithelial ovarian cancer.

Meta- and single-study analyses clearly show the prognostic importance of complete cytoreduction to microscopic disease as OS was significantly prolonged in these groups of women (most

studies showed a large statistically significant greater risk of death in all residual disease groups compared to microscopic disease). RFS was not reported in any of the studies. The fact that all of the studies included at least 50 women and used statistical adjustment for important prognostic factors increased the level of certainty in estimates, despite the fact the review was restricted to non-randomised retrospective studies (see Figure 3).

Only the Zang 2000 study compared sub-optimal (> 1 cm) versus optimal (< 1 cm) cytoreduction and this study showed the importance of trying to debulk the tumour to less than 1 cm if microscopic disease cannot be achieved (HR 3.51, 95% CI 1.84 to 6.70). Similarly, one study (Chi 2006) found that women whose

tumour had been cytoreduced to less than 0.5 cm had less risk of death compared to those with residual disease greater than 0.5 cm (HR not reported; P value < 0.001).

Adverse events, QoL and cost-effectiveness were not reported in any of the studies. QoL may be of additional importance to women who present with recurrent disease and have obvious physical limitations to their life after developing the disease and as a result of the effects of receiving treatment. None of the included studies had QoL assessments as a component of the studies. Treatment-related morbidity very often degrades the quality of the time that people live, which is especially important after the completion of treatment for advanced cancer where people have poor prognosis and will want to enjoy a comfortable standard of living during their final months. However, this needs to be considered in the context of the findings from this review in that women in whom complete cytoreduction is achieved have a much better survival, suggesting that the potential benefits of prolonging survival may outweigh the disadvantages of any short-term morbidities associated with the surgical procedure. Only one study (Zang 2000) compared residual disease greater and less than 1 cm (see above) and one study (Chi 2006) greater or less than 0.5 cm. All of the studies emphasised the importance of making every effort to try and reduce the tumour to microscopic disease.

Overall completeness and applicability of evidence

The evidence from this review indicates that complete (no visible residual disease) and optimal (residual disease < 1 cm) secondary surgical cytoreduction is associated with prolonged survival in recurrent epithelial ovarian cancer compared to sub-optimal (residual disease > 1 cm). Although the findings do not enable us to determine whether it is a direct effect of the surgical intervention that women with complete cytoreduction do better, if surgery is undertaken, every effort should be made to reduce the tumour to microscopic disease. Where this is considered not achievable, attempts should be made to obtain optimal cytoreduction, defined as residual disease less than 1 cm. There was no evidence on whether or not residual disease defined as being less than 2 cm still had any significant survival benefit when compared to residual disease greater than this threshold.

The criteria for assignment of women to secondary cytoreductive surgery were selective in most cases so statistical adjustment was necessary to minimise bias. The review benefited from having restrictive inclusion criteria. By only including studies with 50 or more women, satisfactory conclusions could be made in all of the multivariate analyses as the number of women in each study was adequate. One major limitation of the studies is that they were largely confined to younger women and those with a good performance status (median age in several studies in 50s) and the results may therefore not be generalisable to the wider patient population.

Quality of the evidence

There was a high risk of bias due to the non-randomised studies and retrospective nature of the analyses where, despite statistical adjustment for important prognostic factors, selection bias was still likely to be of particular concern.

The nine studies that met our inclusion criteria included retrospective analyses and were all at a high risk of bias. As

the surgical efforts may vary with age, performance status, and intra-operative events or complications, which were not reported thoroughly, we included only sufficiently large studies that controlled for various co-factors using multivariate analysis in order to reduce the possibility of selection bias. The exact reasons for performing one type of surgery over another were not well documented and it was likely that women in generally poor health would be subjected to less aggressive surgery (or no surgery at all) and thus would be more likely to have larger residual disease. This would most likely result in poorer survival, although we applied strict inclusion criteria and included studies that used statistical adjustment. The studies reported adjusted HR estimates using Cox proportional hazards models. An HR is the best statistic to summarise the difference in risk between two intervention groups over the duration of a study when there is 'censoring', that is the time to death is unknown for some women as they are still alive at the end of the study. All studies were at high risk of bias as they, at most, only satisfied three of the criteria used to assess risk of bias (Figure 2). Many of the individual risk of bias items could not be scored as having low risk of bias given the fact that only non-randomised designs were identified; and we were cautious when deciding whether studies were selectively reported or whether any additional source of bias may have been present and scored most of these items as being unclear.

Potential biases in the review process

A comprehensive search was performed, and all studies were sifted and data extracted by two review authors working independently. We were not restrictive in our inclusion criteria with regards to types of studies as we included non-randomised studies with concurrent comparison groups that used multivariate analyses. We attempted to ensure that we did not overlook any relevant evidence by searching a wide range of reasonable-quality non-randomised study designs (studies that did not have concurrent comparison groups and case series of fewer than 50 women were excluded). A significant threat to the validity of the review is likely to be publication bias, that is studies that did not find the treatment to have been effective may not have been published. We found an insufficient number of studies that met the inclusion criteria to assess this possibility adequately.

Agreements and disagreements with other studies or reviews

The results of this review are consistent with the previously published review by Bristow 2009, which showed a direct correlation between degree of cytoreduction and survival so that for each 10% increase in the proportion of women undergoing complete cytoreductive surgery was associated with a 3.0-month increase in median cohort survival time. He concluded that, among women undergoing operative intervention for recurrent ovarian cancer, the proportion of women undergoing complete cytoreductive surgery is independently associated with overall post-recurrence survival time. For this select group of women, the surgical objective should be resection of all macroscopic disease.

A Cochrane systematic review studying the effects of complete and optimal cytoreduction in the treatment of primary (non-recurrent) epithelial ovarian cancer came to a similar conclusion and recommendation (Elattar 2011), which fits with the natural history of the disease that is most likely to progress in the abdominal cavity before it leads to death. Therefore the beneficial

effects of complete as well as optimal to cytoreduction in the primary setting may continue to be present when surgery is performed in the secondary setting as shown in this review. However, this is with the caveat that optimal surgery may be a strong prognostic indicator in both the primary and recurrent setting and a direct therapeutic effect has yet to be robustly demonstrated.

AUTHORS' CONCLUSIONS

Implications for practice

- In women with recurrent ovarian cancer, ability to achieve surgery with complete cytoreduction (no visible residual disease) is associated with significant improvement in overall survival. However, in the absence of randomised controlled trial evidence, it is not clear whether this is solely due to surgical effect or due to tumour biology. Indirect evidence would support surgery to achieve complete cytoreduction in some women, if this is not possible, the aim should be to debulk disease (nodules

less than 0.5 cm or 1 cm). The risks of major surgery need to be carefully balanced against potential benefits on a case-by-case basis.

Implications for research

- There is a need for a trial that randomly assigns women with recurrent ovarian cancer to surgery.
- Future trials need to clarify which groups of women would benefit from which treatment by stratifying women at trial entry for age, performance status, prior treatments, site of disease and co-morbidity.
- Quality of life and symptom scores should be assessed as well as primary outcomes such as overall survival.

ACKNOWLEDGEMENTS

We thank Jo Morrison for clinical and editorial advice, Jane Hayes for designing the search strategy, and Gail Quinn and Clare Jess for their contribution to the editorial process.

REFERENCES

References to studies included in this review

Ayhan 2006 {published data only}

Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik N, Dursun P, et al. The role of secondary cytoreduction in the treatment of ovarian: Hacettepe University experience. *American Journal of Obstetrics and Gynaecology* 2006;**194**:49-56.

Chi 2006 {published data only}

Chi DS, McCaughy K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. *Cancer* 2006;**106**(9):1933-9.

Eisenkop 2000 {published data only}

Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. *Cancer* 2000;**88**(1):144-53.

Harter 2006 {published data only}

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl Si, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Annals of Surgical Oncology* 2006;**13**(12):1702-10.

Oksefjell 2009 {published data only}

Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. *Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO* 2009;**20**(2):286-93.

Salani 2007 {published data only}

Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. *Cancer* 2007;**109**(4):685-91.

Scarabelli 2001 {published data only}

Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. *Gynecologic Oncology* 2001;**83**:504-12.

TIAN 2010 {published data only}

Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1 - 1 cm after secondary cytoreduction. *Journal of Surgical Oncology* 2010;**101**:244-50.

Zang 2000 {published data only}

Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. *Journal of Surgical Oncology* 2000;**75**(1):24-30.

References to studies excluded from this review

Benedetti 2006 {published data only}

Benedetti Panici P, De Vivo A, Bellati F, Mancini N, Perniola G, Basile S, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. *Annals of Surgical Oncology* 2006;**14**(3):1136-42.

Berek 1983 {published data only}

Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elasooff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. *Obstetrics & Gynecology* 1983;**61**(2):189-93.

Bristow 2003 {published data only}

Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. *Gynecologic Oncology* 2003;**90**(3):519-28.

Bristow 2009 {published data only}

Bristow RE, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. *Gynecologic Oncology* 2009;**114**(2):173-7.

Eisenkop 1995 {published data only}

Eisenkop S M, Friedman R L, Wang H J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. *Cancer* 1995;**76**(9):1606-14.

Gadducci 2000 {published data only}

Gadducci A, Lacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. *Gynecologic Oncology* 2000;**79**(3):344-9.

Goto 2011 {published data only}

Goto T, Takano M, Watanabe A, Miyamoto M, Kato M, Hirata J, et al. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. *International Journal of Gynecological Cancer* 2011;**21**:263-8.

Gronlund 2005 {published data only}

Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. *European Journal of Surgical Oncology* 2005;**31**(1):67-73.

Gungor 2005 {published data only}

Gungor M, Ortak F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. *Gynecologic Oncology* 2005;**97**(1):74-9.

Helm 2007 {published data only}

Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment

of recurrent ovarian carcinoma. *Gynecologic Oncology* 2007;**105**(1):90-6.

Karam 2007 {published data only}

Karam AK, Santillan A, Bristow RE, Giuntoli II R, Gardner GJ, Cass I, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. *Gynecologic Oncology* 2007;**104**(2):377-80.

Landoni 1998 {published data only}

Landoni F, Pellegrino A, Cormio G, Milani R, Maggioni A, Mangioni C. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. *Acta Obstetrica et Gynecologica Scandinavica* 1998;**77**(2):233-7.

Matsumoto 2006 {published data only}

Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. *The Journal of Obstetrics and Gynaecology Research* 2006;**32**(6):580-7.

Morris 1989 {published data only}

Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Gynecologic Oncology* 1989;**34**(3):334-8.

Munkarah 2001 {published data only}

Munkarah A, Levenback C, Wolf JK, Bodurka-Bervers D, Tortolero-Luna G, Morris RT, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. *Gynecologic Oncology* 2001;**81**(2):237-41.

Park 2006 {published data only}

Park JY, Seo SS, Kang S, Lee KB, Yi LS, Seong CH, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. *Gynecologic Oncology* 2006;**103**(3):977-84.

Tay 2002 {published data only}

Tay EH, Grant PT, Gebiski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Obstetrics and Gynecology* 2002;**99**(6):1008-13.

Tebes 2007 {published data only}

Tebes Stephen J, Sayer Robyn A, Palmer James M, Tebes Christine C, Martino Martin A, Hoffman Mitchel S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. *Gynecologic Oncology* 2007;**106**(3):482-7.

Vaccarello 1995 {published data only}

Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL, et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. *Gynecologic Oncology* 1995;**57**(1):61-5.

van der Vange 2000 {published data only}

van der Vange N, van Goethem AR, Zoetmulder FAN, Kaag MM, van de Vaart PJM, ten Bokkel Huinink WW, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. *European Journal of Surgical Oncology (EJSO)* 2000;**26**(7):663-8.

Zang 2000a {published data only}

Zang R-Y, Zhang Z-Y, Li Z-T, Cai S-M, Tang M-Q, Chen J, et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. *European Journal of Surgical Oncology (EJSO)* 2000;**26**(8):798-804.

Zang 2003 {published data only}

Zang R-Y, Li Z-T, Zhang Z-Y, Cai S-M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. *International Journal of Gynecological Cancer* 2003;**13**(4):419-27.

Zang 2004 {published data only}

Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. *Cancer* 2004;**100**(6):1152-61.

Zanon 2004 {published data only}

Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. *World Journal of Surgery* 2004;**28**(10):1040-5.

Additional references

Boente 1998

Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. *Seminars in Oncology* 1998;**25**:326-34.

Bookman 1998

Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. *Journal of Clinical Oncology* 1998;**16**(10):3345-52.

Bristow 2002

Bristow RE, Tomacruz RS, Armstrong DK, Timble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *Journal of Clinical Oncology* 2002;**20**:1248-59.

Burke 1994

Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. *Obstetrics and Gynecology Clinics of North America* 1994;**21**:167-78.

CTCAE 2006

Common Terminology Criteria for Adverse Events v3.0.
www.eortc.be/services/doc/ctc/ctcae3.pdf (accessed 23 January 2013).

Deeks 2001

Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). *Systematic Reviews in Health Care: Meta-Analysis in Context*. 2nd Edition. London: BMJ Publication Group, 2001.

Delgado 1984

Delgado G, Oram DH, Petril ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. *Gynecologic Oncology* 1984;**18**:293-8.

DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;**7**:177-88.

Elattar 2011

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. *Cochrane Database of Systematic Reviews* 2011, Issue 8. [DOI: [10.1002/14651858.CD007565.pub2](https://doi.org/10.1002/14651858.CD007565.pub2)]

EUROCORE 2003

Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al and the EUROCORE Working Group. EUROCORE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. *Annals of Oncology* 2003;**14** Suppl 5:v61-v118.

Galaal 2010

Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. *Cochrane Database of Systematic Reviews* 2010, Issue 6. [DOI: [10.1002/14651858.CD007822.pub2](https://doi.org/10.1002/14651858.CD007822.pub2)]

GLOBOCAN 2008

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. globocan.iarc.fr (accessed 23 January 2013).

Goff 2000

Goff BA, Mander L, Muntz HG. Ovarian carcinoma diagnosis. *Cancer* 2000;**89**(10):2068-75.

Gonzalez-Martin 2003

Gonzalez-Martin AA, Clavo E, Bover I, Rubio J, Arcusa A, Casado A. Randomized phase II study of carboplatin versus paclitaxel-carboplatin in platinum sensitive recurrent advanced ovarian carcinoma with assessment of quality of life. *Proceedings of the American Society of Clinical Oncology* 2003;**22**:abs 1812.

Hacker 1983

Hacker NF, Berek JS, Lagasse CD, Neiberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. *Obstetrics and Gynecology* 1983;**61**:413-20.

Hannibal 2008

Hannibal CG. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five year relative survival. *Acta Obstetrica et Gynecologica Scandinavica* 2008;**87**(12):1353-60.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2008

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.0 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.

Hoskins 1994

Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with sub optimal residual epithelial ovarian carcinoma. *American Journal of Obstetrics and Gynecology* 1994;**70**:974-80.

IARC 2002

Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. IARC Scientific Publication 2002; No. 155 2002.

Jemal 2008

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. *CA: A Cancer Journal for Clinicians* 2008;**58**:71-96.

Markman 2004

Markman M, Markman J, Webster K, Zanolli K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. *Journal of Clinical Oncology* 2004;**22**(15):3120-5.

Munkarah 2004

Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. *Gynecologic Oncology* 2004;**95**(2):273-80.

Ozols 2005

Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M editor(s). *Principles and Practice of Gynecologic Oncology*. 4th Edition. Philadelphia, PA: Lippincott-Raven Publishers, 2005:895-987.

Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**(24):2815-34.

Parmar 2003

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women

with relapsed ovarian cancer. the ICON4/AGO-OVAR-2-2 trial. *Lancet* 2003;**361**:2099-106.

Piver 1988

Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukaso Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma. *Journal of Clinical Oncology* 1988;**6**:983-9.

RevMan 2011 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

Scully 1998

Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology. Vol. **Fascicle 23 3rd series**, Washington, DC: Armed Forces Institute of Pathology, 1998:1-168.

Shepherd 1989

Shepherd JH. Revised FIGO staging for gynaecological cancer. *British Journal of Obstetrics and Gynaecology* 1989;**96**(8):889-92.

Smith 2005

Smith LH, Morris CR, Yasmeeen S. Ovarian cancer: can we make the clinical diagnosis earlier?. *Cancer* 2005;**104**(7):1398-407.

Vergote 2011

Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. *European Journal of Cancer* 2011;**47 Suppl 3**:S88-92.

Wright 2006

Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. *Cancer* 2006;**107**(1):83-9.

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Ayhan 2006

Methods	Retrospective study
Participants	<p>64 women, recurrent EOC, from 1990 to 2001.</p> <p>Mean age of 51 years.</p> <p>Inclusion criteria:</p> <p>Women with recurrent EOC, at least 6 months post primary treatment.</p> <p>Exclusion criteria:</p> <p>Women with progressive disease (recurrence within 6 months of initial surgery).</p> <p>Disseminated intrahepatic or extra-abdominal metastasis.</p> <p>Palliative surgery rather than a cytoreductive effort.</p>
Interventions	<p>Interventions:</p> <p>53 women (83%) had optimal SCR ≤ 1 cm of residual disease (28 women without macroscopic disease and 25 women with residual disease ≤ 1 cm)</p> <p>Comparison:</p> <p>11 women (17%) had sub-optimal cytoreduction > 1 cm residual</p>
Outcomes	<p>Primary outcome:</p> <p>MST for optimally cytoreduced: 28 months.</p> <p>MST for sub-optimally cytoreduced: 18 months.</p> <p>Secondary outcome:</p>

Ayhan 2006 (Continued)

Multivariable analysis showed 3 factors were associated with a favourable outcome after SCR: optimal cytoreduction during primary surgery, optimal cytoreduction during SCR surgery and endometrioid type of tumour histological type.

Analysis of SCR success:

Multivariate analysis of (age, number of recurrent disease and maximal diameter of the recurrence): only **age** (≤ 50 years had 57.6% no macroscopic disease vs. > 50 years had 29% no macroscopic disease) and **number of recurrent disease** (no macroscopic disease in 92% and 31% of women with 1 and ≥ 2 recurrent disease; P value = 0.001) to be significant for maximal SCR.

Notes	<p>33 women (52%) had SCR included only resection of the recurrent tumour.</p> <p>31 women (48%) SCR included additional visceral organ resections (intestinal and bowel resection in 17, splenectomy in 10, partial liver resection in 2 and removal of the bladder in 2).</p> <p>All women received postoperative adjuvant chemotherapy after the SCR.</p> <p>56 women (87%) had chemotherapy only.</p> <p>4 women (6%) had radiation therapy only.</p> <p>4 women (6%) had chemoradiation.</p> <p>Median follow-up: 33.7 months.</p> <p>Outcome of primary surgery was significant for survival after SCR (30 months for optimal vs. 18 months for sub-optimal).</p> <p>DFI significantly affected the OS duration (If DFI < 12 months, the MST was 18 months and if DFI > 12 months the MST up to 39 months).</p> <p>Chemotherapy before SCR has no effect of survival outcome.</p> <p>Authors carried out a multivariate analysis and found that optimal cytoreduction during primary cytoreduction (P value = 0.003), endometrioid-type tumour histology (P value = 0.005) and SCR (HR 0.47, 95% CI 0.22 to 0.99; P value = 0.04) were all significant factors, which indicates that women who had no visible disease after SCR surgery were at less risk of death than those with visible disease. In the meta-analysis, the reference group was reversed so that all forest plots were consistent and a HR > 1 indicated that women with residual disease > 0 cm had increased risk of death compared to those with microscopic disease</p>
-------	---

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Not done as it was retrospective study. Women who had SCR surgery were recruited after an extensive discussion by the multidisciplinary team.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.

Ayhan 2006 (Continued)

Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

Chi 2006

Methods	Retrospective study
Participants	<p>153 women with recurrent EOC from January 1987 to December 2001.</p> <p>Median age of 56.5 years.</p> <p>Inclusion criteria:</p> <p>Women diagnosed with EOC who had undergone primary surgery and received platinum-based chemotherapy.</p> <p>Had completed clinical remission of at least 6 months.</p> <p>For women who underwent second-look surgery and received further chemotherapy, the time of the clinical remission was measured from completion of the therapy after the second-look surgery.</p> <p>Exclusion criteria:</p> <p>Women with low malignant potential.</p> <p>Women who underwent surgery for correction of malignant bowel obstruction.</p>
Interventions	<p>Interventions:</p> <p>62 women (41%) had no macroscopic disease.</p> <p>17 women (11%) had residual disease of 0.1-0.5 cm.</p> <p>21 women (14%) had residual disease of 0.6-1.0 cm.</p> <p>52% of women had residual disease that measure ≤ 0.5 cm.</p> <p>Comparison:</p> <p>11 women (7%) had residual disease of 1.1-2.0 cm.</p> <p>41 women (27%) had residual disease of > 2 cm.</p> <p>1 woman (1%) had residual disease status unknown.</p>
Outcomes	<p>Primary outcome:</p> <p>Median survival of women who had optimal cytoreduction (≤ 0.5 cm) was 56.2 months.</p> <p>MST of women who had sub-optimal cytoreduction (≥ 0.5 cm) was 26.7 months.</p> <p>105 women (69%) died of disease.</p> <p>23 women (15%) remained alive with no evidence of disease.</p>

Chi 2006 (Continued)

25 women (16%) remained alive with disease.

Secondary outcome:

No perioperative mortalities.

6 (4%) intraoperative complications, all which involved bowel injuries.

6 (4%) postoperative complications.

3 women had infectious process requiring antibiotics.

2 women had venous thromboembolism.

1 woman had bleeding secondary to gastritis.

On multivariate analysis:

DFI,

the number of sites of recurrence and

residual disease after SCR retained prognostic significance

Notes

Median OS was 41.7 months.

All women had a CT scan preoperatively.

129 women (84%) received platinum- based chemotherapy after their SCR.

21 women (14%) received non-platinum- based chemotherapy.

3 women (2%) received unknown treatment.

No statistically significant difference between survival of women who were left no macroscopic residual disease that measured from 0.1 cm to 0.5 cm.

Median follow-up was 36.9 months.

Median DFI was 17 months.

MST was 60 months for single site of recurrence.

MST was 42 months for multiple sites of recurrence.

MST was 28 months for women who had carcinosarcoma.

The only continuous factor that had prognostic significance in the univariate analysis was DFI.

In general, the median survival improved significantly with longer DFIs, fewer sites of recurrence and SCR to residual disease that measured ≤ 0.5 cm.

The suggestion from this study was that the objective of SCR should be to achieve residual disease that measures ≤ 0.5 cm.

The following selection criteria are suggested:

For women with only 1 of site of recurrence

DFI is ≥ 6 months

Offer SCR surgery for women with multiple recurrence sites but no carcinosarcoma who have a DFI > 12 months.

For women with carcinosarcoma who have a DFI > 30 months (SCR may be beneficial).

Chi 2006 (Continued)

SCR not recommend for women who have a DFI of 6-12 months with evidence of carcinomatosis.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	This was a retrospective non-randomised study.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	High risk	Lack of specific information on outcomes of comparable women with recurrent disease who were managed without SCR.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

Eisenkop 2000

Methods	Prospective study
Participants	<p>106 women with recurrent epithelial ovarian carcinoma from 1990 to 1998.</p> <p>Median age of 60.5 years.</p> <p>Inclusion criteria:</p> <p>Completion of primary surgery and chemotherapy with a clinical, radiographic and serological DFI of at least 6 months after primary adjuvant chemotherapy.</p> <p>Absence of unresectable extra-abdominal or hepatic metastases.</p> <p>Patient willingness to be treated with chemotherapy or radiation therapy after surgery.</p> <p>Absence of medical contraindications to an extensive surgical procedure.</p> <p>Gynecologic Oncology Group (GOG) performance status < 4.</p>
Interventions	<p>Intervention:</p> <p>87 women (82%) had complete cytoreduction, no visible residual disease.</p> <p>3 women (3%) had residual disease < 5 mm.</p>

Eisenkop 2000 (Continued)

Comparison:

16 women (15%) had residual disease > 5 cm.

Outcomes
Primary outcome:

Complete cytoreduction MST 44.4 months.

Optimal/sub-optimal cytoreduction (any residual disease); MST 19.3 months (P value = 0.007).

Secondary outcome:

2 women (2%) died (1 of multiple organ failure and 1 of sepsis).

34 women (32%) had postoperative complications.

11 women (10%) had wound infection.

27 women (26%) had prolonged ileus.

10 women (9%) had septicaemia.

3 women (3%) had enterocutaneous fistula or pneumonia.

2 women (2%) had systematic candidiasis, partial fascial separation or mechanical small bowel obstruction managed surgically.

1 woman (1%) had a superior vena cava syndrome, cholecystitis, RDS, DVT, pseudomembranous colitis and a vesicovaginal fistula.

Multivariate analysis: use of salvage chemotherapy before surgery, the GOG performance status and size of the largest site of recurrent disease were independent predictor of survival.

Preoperative GOG performance status: survival: 0 (100%), 1 (91%), 2 (82%), 3 (47%); P value = 0.001).

This study confirmed that the completeness of surgical resection independently determines the prognosis and is proven to improve survival.

Notes

Overall MST from date of SCR was 34.4 months.

64 women (60.5%) had secondary surgery before salvage chemotherapy.

42 women (39.5%) had salvage chemotherapy before secondary surgery.

Among the women with bulky unresected disease:

6 women (38%) had open and closed procedure

7 women (44%) had palliative procedure such as gastrostomy or colostomy.

After recovery from surgery, women received salvage therapy based on initial treatment.

34 women (32%) received IV platin-paclitaxel therapy.

24 women (23%) were treated with other platinum-based systemic combination therapy.

7 women (6.5%) were treated with either paclitaxel or platin-based intraperitoneal chemotherapy.

4 women (4%) received whole abdomen radiation therapy.

5 women (5%) did not receive any therapy.

Median survival for women who were not treated with salvage chemotherapy before SCR was 47% and 40% of those women survived > 5 years after recurrence.

Eisenkop 2000 (Continued)

MST for women treated with salvage chemotherapy before secondary surgery was 15.8 months and 15% of those women survived > 5 years after recurrence.

Majority of women had advanced disease at primary diagnosis and bulky, multifocal disease at time of recurrence (87 women (82%) had multifocal disease sites).

Survival was influenced by:

DFI after primary treatment (6-12 months (median 56.8 months) vs. 13-36 months (median 44.4 months) vs. > 36 months (median 56.8 months); P value = 0.007)

The use of salvage chemotherapy before secondary surgery (chemotherapy given (median 24.9 months) vs. chemotherapy not given (median 48.4 months); P value = 0.005)

Largest size of recurrent tumour (< 10 cm (median 37.3 months) vs. > 10 cm (median 35.6 months); P value = 0.04).

The probability of complete cytoreduction was influenced by:

The largest size of recurrent tumour (< 10 cm (90%) vs. > 10 cm (67%); P value = 0.001). Women with metastases > 10 cm in largest dimension were rendered visibly disease free 67% of the time.

Use of salvage chemotherapy before secondary surgery (chemotherapy given (64%) vs. chemotherapy not given (94%); P value = 0.001).

Log rank analysis revealed the DFI, use of salvage chemotherapy before secondary surgery, the largest size of recurrence disease and cytoreductive outcome to influence the probability of survival.

Patient age, GOG performance status, tumour grade, histology, presence or absence of ascites, location of largest recurrence tumour, sub-speciality training of physician involved at primary surgery, the number or specific types of procedures performed at secondary surgery and the presence or absence of symptoms, physical findings, or preoperative radiographic findings of ascites, retroperitoneal lymph nodes, or other intra-abdominal masses did not influence the probability of survival.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	A prospective study, no randomisation.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.

Eisenkop 2000 (Continued)

Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.
--------------------------	----------	--

Harter 2006

Methods	Retrospective study (DESKTOP OVARIAL TRIAL)
Participants	<p>267 women with recurrent EOC.</p> <p>Median age 60 years</p> <p>From January 2000 to December 2003 from 25 institutions</p> <p>Exclusion criteria:</p> <p>Women with non-EOC.</p> <p>Women with borderline tumours.</p> <p>Women who had operations with palliative purposes or within primary therapy (second-look or interval operations).</p>
Interventions	<p>Intervention:</p> <p>133 women (50%) had complete cytoreduction.</p> <p>69 women (26%) had optimal cytoreduction (residual tumour of 1-10 mm).</p> <p>Comparison:</p> <p>22 women (8%) had sub-optimal cytoreduction (residual tumour of 11-20 mm).</p> <p>43 women (16%) had sub-optimal cytoreduction (residual tumour of > 20 mm).</p>
Outcomes	<p>MST of complete cytoreduction (without residual tumour) was 45.2 months.</p> <p>MST with residual tumour, irrespective of its size was 19.7 months (HR 4.33, 95% CI; P value < 0.0001).</p> <p>The size of residual tumour did not impact survival in women not completely debulked.</p> <p>MST of women with residual tumour of 1-10 mm and > 10 mm was 19.6 and 19.7 months, respectively (P value = 0.502).</p> <p>Multivariate analysis:</p> <p>Significant factors for survival following SCR.</p> <p>Complete cytoreduction (residual tumour at surgery for recurrence 0 vs. > 0 mm; P value < 0.001).</p> <p>Absence of ascites.</p> <p>Application of a platinum-containing chemotherapy.</p>
Notes	<p>168 women (63%) had DFI was 12 months from primary surgery.</p> <p>92% had a good performance status (ECOG).</p> <p>69% had advanced disease at initial diagnosis.</p> <p>Some women had salvage chemotherapy before the surgery.</p> <p>All women received platinum-based first-line chemotherapy.</p>

Surgical cytoreduction for recurrent epithelial ovarian cancer (Review)

Harter 2006 (Continued)

73% had recurrent disease localised beyond the pelvis.

Post SCR treatment with platinum-based chemotherapy in 47%.

43% had received other chemotherapy.

No postoperative chemotherapy was documented for 10.5%.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	A retrospective study, no randomisation.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

Oksefjell 2009

Methods	Retrospective study
Participants	<p>789 women treated for the first recurrence EOC from 1985 to 2000</p> <p>217 women with EOC who had any surgical procedure following primary debulking and chemotherapy.</p> <p>Inclusion criteria:</p> <p>Surgery for cytoreduction or for bowel obstruction.</p> <p>Non-responders to chemotherapy during primary treatment.</p> <p>Tumour relatively localised in pelvis or upper abdomen.</p> <p>Age, good performance status and TFI > 6 months.</p> <p>Exclusion criteria:</p> <p>Women with borderline tumours.</p>

Oksefjell 2009 (Continued)

571 women who got only chemotherapy at first relapse.

Interventions	<p>Intervention:</p> <p>68 women (35%) without macroscopic tumour.</p> <p>Complete cytoreduction was achieved in 49% of women operated with SCR intentions.</p> <p>Comparison:</p> <p>33 women (17%) having tumour nodules ≤ 2 cm residual tumours.</p> <p>21 women operated for bowel obstruction were excluded from statistical analysis biopsy the residual tumour after SCR was not registered.</p>
Outcomes	<p>Primary outcome:</p> <p>MST was 4.5 years in women who were SCR to no residuum compare to 0.7 years in women left with residual disease > 2 cm and 2.3 years when ≤ 2 cm macroscopic disease was left.</p> <p>Multivariate analysis:</p> <p>Residual tumour after SCR, TFI and age as independent prognostic factors for survival.</p> <p>Localised tumour remained as prognostic factor in binary logistic regression.</p> <p>There is a clear survival benefit for women who had undergone a secondary complete cytoreduction followed by chemotherapy compared with chemotherapy alone at the time of first recurrence.</p>
Notes	<p>Treatment of the first relapse was registered in 3 groups:</p> <ul style="list-style-type: none"> • no surgery; • surgery for local disease (1 or 2 lesions in abdomen or pelvis and refers to what is found during the operation); • surgery for disseminated disease. <p>Ascites and performance status were not always registered.</p> <p>Types of chemotherapy:</p> <p>Either as chemotherapy alone or as post-SCR therapy.</p> <p>SCR was chosen for 217 (27%) of 789 women with recurrence EOC.</p> <p>At relapse significantly more women with TFI > 24 months had SCR.</p> <p>Significantly more women > 70 years had chemotherapy.</p> <p>84 of 217 women had localised disease and MST was 3.4 years.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	A retrospective study, no randomisation.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.

Oksefjell 2009 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques which were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

Salani 2007

Methods	Retrospective study
Participants	<p>55 women with recurrent EOC from September 1997 to March 2005.</p> <p>Median age at recurrent was 57.7 years.</p> <p>Inclusion criteria:</p> <p>Complete a clinical response to the primary therapy.</p> <p>≥ 12 months between the initial diagnosis and recurrence.</p> <p>Performance status ≤ 2.</p> <p>Attempted SCR.</p> <p>≤ 5 recurrence sites within the abdomen or pelvis on preoperative imaging studies.</p> <p>Exclusion criteria:</p> <p>Women who underwent an interval debulking or second-look procedure with findings of macroscopically positive disease.</p>
Interventions	<p>Intervention:</p> <p>Complete cytoreduction was achieved in 41 women (74.5%).</p> <p>8 women (14.5%) had optimal cytoreduction (macroscopic disease with a maximal dimension < 1 cm).</p> <p>Comparison:</p> <p>6 women (11%) had sub-optimal cytoreduction (> 1 cm of residual disease).</p>
Outcomes	<p>Primary outcome:</p> <p>MST for women who had complete cytoreduction after SCR was 50 months (41 women).</p> <p>MST for women who had sub-optimal cytoreduction (macroscopic residual disease) was 7.2 months (14 women) (P value = 0.0001).</p>

Surgical cytoreduction for recurrent epithelial ovarian cancer (Review)

Salani 2007 (Continued)

Secondary outcome:

Postoperative complications occurred in 14 women (25.5%):

5 women had febrile morbidity.

5 women had ileus.

2 women had respiratory complications.

1 woman had wound dehiscence.

1 woman had pelvic haematoma.

1 (2%) woman had perioperative death (septic shock).

Multivariate analysis: the statistical significant and independent predictors of OS were:

Diagnosis to recurrence interval ≥ 18 months (MST was 49 months vs. 3 months; P value < 0.01).

Number of radiological recurrence sites (MST of 50 months for women with 1 or 2 sites vs. 12 months for women with 3 to 5 sites; P value < 0.03).

Residual disease (MST was 50 months for women with no macroscopic residual disease vs. 7.2 months for women with macroscopic residual disease; P value < 0.01).

Age, tumour, grade, histology, Ca125 level, ascites and tumour size were not associated significantly with survival.

Notes

Median follow-up was 30 months.

Median diagnosis to recurrent interval was 32 months.

A time of SCR the median Ca125 level was 56 U/mL.

MST from time of SCR was 48 months suggesting that women with ≤ 5 lesions on imaging studies, comprise a group with a good prognosis

Median survival advantage > 3 years for women who were limited to 1 or 2 recurrence sites compared with women who had 3 to 5 recurrence sites based on both imaging studies and surgical exploration.

The major end point of this study was the association of clinical factors with post recurrence survival outcome.

Preoperative imaging studies correctly predicted the number of recurrence site in 34 of 55 women (62%) and those predications were confirmed by the operative and pathology reports.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	A retrospective study, no randomisation.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias)	Low risk	Women were analysed for OS using appropriate statistical techniques which were used to account for any censoring.

Salani 2007 (Continued)

All outcomes

Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

Scarabelli 2001

Methods	Prospective study
Participants	<p>149 women with recurrent EOC from June 1993 to June 1999</p> <p>Inclusion criteria:</p> <p>age $\leq$ 75 years.</p> <p>Karnofsky performance status $\geq$ 60.</p> <p>RFI > 6 months from primary treatment.</p> <p>Radiographic or physical findings suggestive recurrence.</p> <p>Absence of unresectable extra-abdominal or hepatic metastases.</p> <p>Patient willingness to be treated with chemotherapy after recovery of surgery.</p> <p>Absence of medical contraindications to an extensive surgical procedure.</p> <p>Exclusion criteria:</p> <p>SCR during second-look laparotomy.</p> <p>Interval cytoreduction.</p> <p>SCR in women with radiographic or physical findings suggestive of progressive disease during primary or any salvage chemotherapy.</p> <p>Palliative surgery in women with intestinal obstruction.</p> <p>Presence of other malignancies except for basal cell carcinoma.</p>
Interventions	<p>Intervention:</p> <p>53 women (35.5%) had complete cytoreduction.</p> <p>51 women (34.5%) had optimal cytoreduction (residual disease < 1 cm in diameter).</p> <p>Comparison:</p> <p>45 women (30%) had sub-optimal cytoreduction of > 1 cm intra-abdominal residual disease.</p>
Outcomes	Primary outcome:

Scarabelli 2001 (Continued)

The OS according to residual tumour after secondary surgery in 69 women with DFI of 7-12 months: the estimated 2-year survival rates were:

56% for no macroscopic disease.

9% for < 1 cm residual disease.

6% for > 1 cm residual disease; P value < 0.001.

The OS according to residual tumour after secondary surgery in 59 women with DFI of 13-24 months:

2-year survival rates were:

91% for no macroscopic disease.

49% for < 1 cm residual disease.

17% for > 1 cm residual disease.

The estimated 5-year survival was 53% for women with no macroscopic disease.

None of the women with < 1 cm and > 1 cm outlived the 4-year estimate.

The estimated 2-year survival rates for women with DFI > 24 months were:

14% for no macroscopic disease

53% for < 1 cm residual disease

14% for > 1 cm residual disease

None of these women outlived the 4-year estimate

Secondary outcome:

Median blood units transfused was 3 units

Perioperative complications in 39 women (26%):

10 women (7%) had severe haemorrhages (estimated blood loss > 1000 mL).

7 women (5%) had ureteral lesions.

10 women (7%) had vesical lesions.

12 women (8%) had bowel lesions.

Postoperative complications in 24 women (16%).

2 women (1%) had enterocutaneous.

5 women (3%) had enterovaginal fistula.

2 women (1%) had vesical fistula.

5 women (3%) had ureteral fistula.

7 women (5%) had septicaemia.

3 women (2%) had pulmonary embolism

5 women (3%) died (2 of multiple organ failure, 2 of sepsis and 1 of pulmonary embolism) within 30 days of surgery.

Multivariate analysis RFI, prior chemotherapy combination and residual tumour after secondary surgery were associated independently with OS.

Scarabelli 2001 (Continued)

Residual tumour after secondary surgery was by far the most strongly predictive factor for patient's survival.

Notes

Median follow-up was 27 months.

Multivariate analysis

Unexpectedly, RFI > 24 months was not correlated significantly with OS. The explanation for this difference was that 17 women (81%) with RFI > 24 months were heavily treated with chemotherapy before surgery.

The number of chemotherapy combinations from primary surgery significantly influenced survival for women with RFI 13-24 months and > 24 months.

The median estimated survival related to 1 or > 1 previous chemotherapy treatment was 16 vs. 12 months in women with RFI of 7-12 months, 45 vs. 10 months in women with RFI 13-24 months and 35 vs. 13 months in women with RFI > 24 months.

In conclusion, the current study demonstrates a significant survival advantage for women who undergo complete SCR surgery, but despite improved survival, the long-term prognosis remained poor

Women with platinum-resistant disease have an extremely unfavourable prognosis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	A prospective study, no randomisation.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques which were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

TIAN 2010

Methods	Retrospective study
Participants	123 women with recurrent epithelial ovarian tumour from 2002 to 2006.

TIAN 2010 (Continued)

Median age 51 years.

Inclusion criteria:

PFI > 6 months.

ECOG performance status ≤ 2

Exclusion criteria:

Women with low malignant potential tumours.

Non-EOCs.

Interventions
Intervention:

97 women (79%) optimal cytoreduction ≤ 1 cm.

51 women (41.5%) had complete cytoreduction (R0 cytoreduction) (complete).

46 women (37.5%) had optimal cytoreduction (R1 cytoreduction) (residual disease 0.1-1 cm).

Comparison:

26 women (21%) had sub-optimal cytoreduction (R2) (residual disease > 1 cm).

Outcomes
Primary outcomes:

Mean survival of women who had (R0) complete cytoreduction was 63.2 months.

Mean survival of women who had (R1) optimal cytoreduction was 31.1 months.

Mean survival of women who had (R2) sub-optimal cytoreduction 15.6 months.

The estimated 5-year survival had reached 54% for women with relapsed ovarian cancer who underwent cytoreduction of R0.

When optimal cytoreduction was defined as residual disease ≤ 1 cm, 5-year survival reached 38% in 79% of women with optimal surgical outcomes.

During follow-up:

63 women (51%) died of disease progression.

32 women (26%) were alive with disease.

28 women (23%) were still alive without evidence of recurrence.

Women with R2 were at highest death risk at 12 months after SCR.

Women with R1 were at highest death risk at 2 peaks at 12 and 38 months after SCR.

Women with R0 were at highest death risk at 24 months after SCR.

Secondary outcome:

No perioperative mortality.

5 women (4%) developed major perioperative complications:

1 woman had pelvic haematoma

1 woman had uretero-vaginal fistula

1 woman had vesicovaginal fistula

1 woman had bacterial infection of cutaneous wound.

TIAN 2010 (Continued)

1 woman had mycotic infection of gastrointestinal tract.

Residual disease after SCR alone was the independent prognostic factor determined by **multivariate analysis**. It suggests that R0 is the strongest determinant of survival and should be the first consideration in patient selection for SCR.

Notes

MST after SCR was 31.7 months.

Median follow-up duration: 26.1 months.

PFI was 16.1 months.

48 women (39%) developed the recurrence within 12 months.

39 women (32%) between 13 and 24 months.

36 women (29%) had more than 24 months.

Obvious ascites (> 500 mL) was found in 13 women (10.5%).

Solitary recurrence in 49 women (40%).

Multiple recurrence in 75 women (60%).

5 years' observation study.

MST with solitary lesion was 44.1 months vs. 28.1 months for multiple sites of recurrence; P value = 0.03.

MST of women with lesions > 10 cm was 14.6 months vs. 38.3 months for lesion < 10 cm; P value = 0.03.

Optimal cytoreduction obtained for 43 women (88%) with solitary lesion and for 55 women (73%) with multiple lesions.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Not done as this was a retrospective study.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.

TIAN 2010 (Continued)

Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.
--------------------------	----------	--

Zang 2000

Methods	Retrospective study
Participants	<p>60 women with recurrent EOC from January 1986 to December 1997.</p> <p>Median age of 49 years.</p> <p>Inclusion criteria:</p> <p>The interval of the clinical remission had to be at least of 6 months from primary treatment (surgery and platinum-based chemotherapy) for stage III and IV EOC.</p> <p>Secondary surgery done with therapeutic intent.</p> <p>Exclusion criteria:</p> <p>Interval cytoreductive surgery.</p> <p>Second-look laparotomy.</p> <p>Women who have stable or progressive disease while receiving first-line chemotherapy after primary cytoreductive surgery.</p>
Interventions	<p>Intervention:</p> <p>23 women (38%) had optimal cytoreduction (residual disease ≤ 1 cm).</p> <p>Comparison:</p> <p>37 women (62%) had sub-optimal cytoreduction (residual disease > 1 cm).</p>
Outcomes	<p>Primary outcome:</p> <p>MST was 19 months for women who had optimal cytoreduction.</p> <p>MST was 8 months for women with sub-optimal cytoreduction.</p> <p>Secondary outcome:</p> <p>No postoperative deaths.</p> <p>Postoperative complications in 5%:</p> <p>wound infection, lung infection and ileus in 1 woman each.</p> <p>Logistic stepwise regression revealed that:</p> <p>recurrent ascites (P value = 0.007) and residual disease after SCR (P value = 0.01) were important determinant of SCR outcome.</p>
Notes	<p>Ascites presented in 15 women (25%) at disease recurrence.</p> <p>Second-line chemotherapy was administered in 11 women before SCR.</p> <p>Multivariate analysis showed:</p> <p>3 major prognostic factors affected survival after SCR surgery: residual disease, ascites at recurrence and PFI.</p>

Zang 2000 (Continued)

Residual disease after initial operation was not an independent factor of survival but it affected the secondary surgical attempt.

Preoperative second-line chemotherapy was not a variable influencing second debulking surgery (optimal cytoreduction was achieved in 7 of 11 women (64%) who received chemotherapy preoperatively).

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	This was a retrospective non-randomised study.
Allocation concealment (selection bias)	High risk	Concealment of allocation irrelevant to this study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Women were analysed for OS using appropriate statistical techniques that were used to account for any censoring.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.
Other bias	High risk	No details of women who received chemotherapy pre- and post-SCR.
Representative sample?	Low risk	All women had recurrent ovarian cancer that had been cytoreduced via SCR surgery.
Comparability of groups?	Low risk	Multivariate analysis was used to adjust for important prognostic factors in Cox model for OS.

CI: confidence interval; CT: computed tomography; DFI: disease-free interval; DVT: deep vein thrombosis; ECOG: Eastern Cooperative Oncology Group; EOC: epithelial ovarian cancer; GOG: Gynaecologic Oncology Group; HR: hazard ratio; IV: intravenous; MST: median survival time; OS: overall survival; PFI: Progression-free interval; RDS: respiratory distress syndrome; RFI: recurrence-free interval; SCR: secondary cytoreduction; TFI: treatment-free interval.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Benedetti 2006	47 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Berek 1983	32 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Bristow 2003	22 women in the study (the review excluded case-control studies and case series of fewer than 30 women). The aim of the study was to evaluate the utility of combined PET/CT for identifying ovarian cancer tumour ≥ 1 cm in women with clinically occult recurrent disease by conventional CT imaging.
Bristow 2009	Retrospective study with no comparison group.

Study	Reason for exclusion
	The study concentrated on the clinical outcome of women undergoing rectosigmoid colectomy as a component of secondary cytoreductive surgery for recurrent ovarian cancer.
Eisenkop 1995	36 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Gadducci 2000	36 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Goto 2011	Included women with disease-free interval less than 6 months.
Gronlund 2005	36 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Gungor 2005	44 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Helm 2007	18 women in the study (the review excluded case-control studies and case series of fewer than 30 women).
Karam 2007	A retrospective study of tertiary cytoreduction.
Landoni 1998	38 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Matsumoto 2006	46 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Morris 1989	30 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Munkarah 2001	25 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Park 2006	14 women with recurrent epithelial ovarian carcinoma in the study (the review excluded case-control studies and case series of fewer than 50 women). The study was mainly to assess the safety, efficacy and impact on survival of low anterior resection and primary anastomosis at the time of en bloc resection for primary and recurrent epithelial ovarian carcinoma.
Tay 2002	46 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
Tebes 2007	Used percentage rather than actual participant numbers in analysis of the data.
Vaccarello 1995	23 women in the study (the review excluded case-control studies and case series of fewer than 50 women).
van der Vange 2000	5 women involved (the review excluded case-control studies and case series of fewer than 50 women).
Zang 2000a	This study combined the 6 months of recurrent epithelial ovarian cancer group and the interval cytoreductive surgery group.
Zang 2003	This retrospective study did not report the results of secondary surgery by residual disease. Instead the authors included the effect of giving the women 'redebunking surgery' or secondary chemotherapy in a multivariate Cox regression analysis for overall survival.

Study	Reason for exclusion
Zang 2004	Included women with disease-free interval less than 6 months.
Zanon 2004	30 women in the study (the review excluded case-control studies and case series of fewer than 50 women).

CT: computed tomography; PET: positron emission tomography.

DATA AND ANALYSES

Comparison 1. Residual disease (RD) > 0 cm versus microscopic disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	2	331	Hazard Ratio (Random, 95% CI)	2.62 [1.67, 4.11]

Analysis 1.1. Comparison 1 Residual disease (RD) > 0 cm versus microscopic disease, Outcome 1 Overall survival.

Study or subgroup	RD > 0 cm N	RD 0 cm N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Random, 95% CI	Weight	Hazard Ratio IV, Random, 95% CI
Ayhan 2006	36	28	0.8 (0.38)		36.32%	2.14[1.02,4.5]
Harter 2006	134	133	1.1 (0.287)		63.68%	2.94[1.68,5.17]
Total (95% CI)					100%	2.62[1.67,4.11]
Heterogeneity: Tau ² =0; Chi ² =0.45, df=1(P=0.5); I ² =0%						
Test for overall effect: Z=4.21(P<0.0001)						

Favours RD > 0 cm 0.1 0.2 0.5 1 2 5 10 Favours RD 0 cm

Comparison 2. Residual disease (RD) ≤ 1 cm versus microscopic disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	2		Hazard Ratio (Random, 95% CI)	2.91 [1.78, 4.77]

Analysis 2.1. Comparison 2 Residual disease (RD) ≤ 1 cm versus microscopic disease, Outcome 1 Overall survival.

Study or subgroup	Sub-optimal group N	Microscopic group N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Random, 95% CI	Weight	Hazard Ratio IV, Random, 95% CI
Scarabelli 2001	0	0	1 (0.32)		62.14%	2.64[1.41,4.94]
TIAN 2010	0	0	1.2 (0.41)		37.86%	3.42[1.53,7.64]

Favours > 2 cm group 0.1 0.2 0.5 1 2 5 10 Favours 0 cm group

Comparison 3. Residual disease (RD) ≤ 2 cm versus microscopic disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	1		Hazard Ratio (Random, 95% CI)	Subtotals only

Analysis 3.1. Comparison 3 Residual disease (RD) ≤ 2 cm versus microscopic disease, Outcome 1 Overall survival.

Comparison 4. Residual disease (RD) >1 cm versus microscopic disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	2		Hazard Ratio (Random, 95% CI)	6.80 [3.95, 11.71]

Analysis 4.1. Comparison 4 Residual disease (RD) >1 cm versus microscopic disease, Outcome 1 Overall survival.

Comparison 5. Residual disease (RD) > 2 cm versus microscopic disease

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	1		Hazard Ratio (Random, 95% CI)	Subtotals only

Analysis 5.1. Comparison 5 Residual disease (RD) > 2 cm versus microscopic disease, Outcome 1 Overall survival.

Study or subgroup	Sub-optimal group N	Microscopic group N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Random, 95% CI	Weight	Hazard Ratio IV, Random, 95% CI
Oksefjell 2009	0	0	2 (0.26)		0%	7.69[4.62,12.8]
Favours > 2 cm group				0.05 0.2 1 5 20	Favours 0 cm group	

Comparison 6. Residual disease (RD) > 1 cm versus RD ≤ 1 cm

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	1		Hazard Ratio (Random, 95% CI)	Subtotals only

Analysis 6.1. Comparison 6 Residual disease (RD) > 1 cm versus RD ≤ 1 cm, Outcome 1 Overall survival.

Study or subgroup	RD > 1 cm N	RD ≤ 1 cm N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Random, 95% CI	Weight	Hazard Ratio IV, Random, 95% CI
Zang 2000	0	0	1.3 (0.33)		0%	3.51[1.84,6.7]
Favours RD >1cm				0.1 0.2 0.5 1 2 5 10	Favours RD ≤1cm	

Comparison 7. Overall survival

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	5		Hazard Ratio (Random, 95% CI)	3.59 [2.45, 5.24]
1.1 Residual disease (RD) of any size vs. microscopic disease	2		Hazard Ratio (Random, 95% CI)	2.62 [1.67, 4.11]
1.2 RD ≤ 1 cm vs. microscopic disease	2		Hazard Ratio (Random, 95% CI)	2.91 [1.45, 5.84]
1.3 RD ≤ 2 cm vs. microscopic disease	1		Hazard Ratio (Random, 95% CI)	2.18 [1.08, 4.42]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.4 RD > 1 cm vs. microscopic disease	2		Hazard Ratio (Random, 95% CI)	6.80 [3.15, 14.66]
1.5 RD > 2 cm vs. microscopic disease	1		Hazard Ratio (Random, 95% CI)	7.69 [3.72, 15.88]

Analysis 7.1. Comparison 7 Overall survival, Outcome 1 Overall survival.

Study or subgroup	RD > 0 cm N	RD 0 cm N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Random, 95% CI	Weight	Hazard Ratio IV, Random, 95% CI
7.1.1 Residual disease (RD) of any size vs. microscopic disease						
Ayhan 2006	36	28	0.8 (0.38)		14.28%	2.14[1.02,4.5]
Harter 2006	134	133	1.1 (0.287)		18.69%	2.94[1.68,5.17]
Subtotal (95% CI)					32.97%	2.62[1.67,4.11]
Heterogeneity: Tau ² =0; Chi ² =0.45, df=1(P=0.5); I ² =0%						
Test for overall effect: Z=4.21(P<0.0001)						
7.1.2 RD ≤ 1 cm vs. microscopic disease						
Scarabelli 2001	0	0	1 (0.45)		11.7%	2.64[1.09,6.37]
TIAN 2010	0	0	1.2 (0.58)		8.26%	3.42[1.1,10.66]
Subtotal (95% CI)					19.96%	2.91[1.45,5.84]
Heterogeneity: Tau ² =0; Chi ² =0.13, df=1(P=0.72); I ² =0%						
Test for overall effect: Z=3(P=0)						
7.1.3 RD ≤ 2 cm vs. microscopic disease						
Oksefjell 2009	0	0	0.8 (0.36)		15.13%	2.18[1.08,4.42]
Subtotal (95% CI)					15.13%	2.18[1.08,4.42]
Heterogeneity: Not applicable						
Test for overall effect: Z=2.17(P=0.03)						
7.1.4 RD > 1 cm vs. microscopic disease						
Scarabelli 2001	0	0	1.8 (0.48)		10.77%	5.81[2.27,14.89]
TIAN 2010	0	0	2.2 (0.68)		6.47%	9.3[2.45,35.26]
Subtotal (95% CI)					17.23%	6.8[3.15,14.66]
Heterogeneity: Tau ² =0; Chi ² =0.32, df=1(P=0.57); I ² =0%						
Test for overall effect: Z=4.89(P<0.0001)						
7.1.5 RD > 2 cm vs. microscopic disease						
Oksefjell 2009	0	0	2 (0.37)		14.7%	7.69[3.72,15.88]
Subtotal (95% CI)					14.7%	7.69[3.72,15.88]
Heterogeneity: Not applicable						
Test for overall effect: Z=5.51(P<0.0001)						
Total (95% CI)					100%	3.59[2.45,5.24]
Heterogeneity: Tau ² =0.12; Chi ² =11.87, df=7(P=0.11); I ² =41.02%						
Test for overall effect: Z=6.59(P<0.0001)						
Test for subgroup differences: Chi ² =10.97, df=1 (P=0.03), I ² =63.54%						

Favours RD > 0 cm 0.02 0.1 1 10 50 Favours RD 0 cm

APPENDICES

Appendix 1. FIGO staging

Stage I

Stage I ovarian cancer is limited to the ovaries.

- Stage IA: tumour limited to 1 ovary; capsule intact, no tumour on ovarian surface. No malignant cells in ascites or peritoneal washings.*
- Stage IB: tumour limited to both ovaries; capsules intact, no tumour on ovarian surface. No malignant cells in ascites or peritoneal washings.*
- Stage IC: tumour limited to 1 or both ovaries with any of the following: capsule ruptured, tumour on ovarian surface, malignant cells in ascites or peritoneal washings.

* [Note: the term malignant ascites is not classified. The presence of ascites does not affect staging unless malignant cells are present.]

Stage II

Stage II ovarian cancer is tumour involving 1 or both ovaries with pelvic extension or implants (or both).

- Stage IIA: extension or implants (or both), on the uterus, fallopian tubes, or uterus and fallopian tubes. No malignant cells in ascites or peritoneal washings.
- Stage IIB: extension to or implants on (or both) other pelvic tissues. No malignant cells in ascites or peritoneal washings.
- Stage IIC: pelvic extension or implants (stage IIA or stage IIB) (or both) with malignant cells in ascites or peritoneal washings.

Different criteria for allotting cases to stage IC and stage IIC have an impact on diagnosis. To assess this impact, of value would be to know if rupture of the capsule was (1) spontaneous or (2) caused by the surgeon; and, if the source of malignant cells detected was (1) peritoneal washings or (2) ascites.

Stage III

Stage III ovarian cancer is tumour involving 1 or both ovaries with microscopically confirmed peritoneal implants outside the pelvis. Superficial liver metastasis equals stage III. Tumour is limited to the true pelvis but with histologically verified malignant extension to small bowel or omentum.

- Stage IIIA: microscopic peritoneal metastasis beyond pelvis (no macroscopic tumour).
- Stage IIIB: macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension.
- Stage IIIC: peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension or regional lymph node metastasis (or both).

Stage IV

Stage IV ovarian cancer is tumour involving 1 or both ovaries with distant metastasis. If pleural effusion is present, positive cytological test results must exist to designate a case to stage IV. Parenchymal liver metastasis equals stage IV ([Shepherd 1989](#)).

Appendix 2. MEDLINE search strategy

- 1 exp Ovarian Neoplasms/
- 2 (ovar* adj5 cancer*).mp.
- 3 (ovar* adj5 neoplas*).mp.
- 4 (ovar* adj5 carcinom*).mp.
- 5 (ovar* adj5 malignan*).mp.
- 6 (ovar* adj5 tumor*).mp.
- 7 (ovar* adj5 tumour*).mp.
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9 exp Surgical Procedures, Operative/

10 surg*.mp.
11 "surgery".fs.
12 11 or 10 or 9
13 debulk*.mp.
14 cytoreduc*.mp.
15 13 or 14
16 8 and 12 and 15
17 "randomized controlled trial".pt.
18 "controlled clinical trial".pt.
19 randomized.ab.
20 randomly.ab.
21 trial.ab.
22 groups.ab.
23 exp Cohort Studies/
24 cohort*.mp.
25 case adj series.mp.
26 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 16 and 26
key: mp=title, original title, abstract, name of substance word, subject heading word
fs=floating subheading

Appendix 3. EMBASE search strategy

EMBASE Ovid

1. exp Ovary Tumor/
2. (ovar* adj5 cancer*).mp.
3. (ovar* adj5 neoplas*).mp. [
4. (ovar* adj5 carcinom*).mp.
5. (ovar* adj5 malignan*).mp.
6. (ovar* adj5 tumor*).mp.]
7. (ovar* adj5 tumour*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Surgery/
10.surg*.mp.
11.su.fs.
12.9 or 10 or 11
13.debulk*.mp.
14.cytoreduc*.mp.
15.13 or 14
16.8 and 12 and 15
17.exp Controlled Clinical Trial/
18.random*.mp.
19.trial*.mp.
20.group*.mp.
21.exp Cohort Analysis/
22.cohort*.mp.
23.series.mp.
24.17 or 18 or 19 or 20 or 21 or 22 or 23
25.16 and 24

key: mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name,
fs=floating subheading

Appendix 4. CENTRAL search strategy

CENTRAL, Issue 11 2012

1. MeSH descriptor Ovarian Neoplasms explode all trees

2. ovar* near/5 cancer*
3. ovar* near/5 neoplas*
4. ovar* near/5 carcinom*
5. ovar* near/5 malignan*
6. ovar* near/5 tumor*
7. ovar* near/5 tumour*
8. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
9. MeSH descriptor Surgical Procedures, Operative explode all trees
- 10.surg*
- 11.Any MeSH descriptor with qualifier: SU
- 12.(#9 OR #10 OR #11)
- 13.debulk*
- 14.cytoreduc*
- 15.(#13 OR #14)
- 16.(#8 AND #12 AND #15)

WHAT'S NEW

Date	Event	Description
21 September 2016	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 10, 2010

Review first published: Issue 2, 2013

Date	Event	Description
11 February 2015	Amended	Contact details updated.
27 March 2014	Amended	Contact details updated.
29 January 2013	Amended	Contact details updated

CONTRIBUTIONS OF AUTHORS

Thuria Al Rawahi is the main author; she reviewed the papers and drafted the review.

Khadra Galaal provided the clinical expertise, developed the protocol and search strategy, performed the search, reviewed the papers and wrote the full review. KG was the primary author of the protocol.

Alberto Lopes assisted in developing the search strategy, reviewed the papers, assisted in writing the review and edited the final version.

Ahmed Elattar contributed to the writing of the review.

Rob Bristow also contributed to the writing of the review, provided clinical expertise and edited the edited the final version.

Andrew Bryant drafted the methodological sections of the protocol and the review.

All authors agreed the final version.

DECLARATIONS OF INTEREST

None.

SOURCES OF SUPPORT

Internal sources

- Department of Obstetrics and Gynaecology, Royal Cornwall Hospital, Truro, UK.

External sources

- Department of Health, UK.

NHS Cochrane Collaboration programme Grant Scheme CPG-506

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We did not find any relevant ongoing trials or active trial groups, so we did not make any contacts. The following sentence in the 'Unpublished and Grey literature' sub-section in the 'searching other resources' part of the methods was removed:

"Searching other resources

"The main investigators of any relevant ongoing trials will be contacted for further information, as will any major co-operative trials groups active in this area."

Adverse events, QoL or other continuous outcomes were not reported in any of the studies so sections in the review that discussed the handling of dichotomous and continuous data were removed as they were unnecessary.

"Data extraction and management

- For dichotomous outcomes (e.g. adverse events), we will extract the number of patients in each group who experience the outcome of interest and the number of patients assessed at endpoint, in order to estimate a risk ratio.
- For continuous outcomes (e.g. quality of life measures), we will extract the final value and standard deviation of the outcome of interest and the number of patients assessed at endpoint in each treatment arm at the end of follow-up, in order to estimate the mean difference between treatment arms and its standard error.

Measures of treatment effect

- For dichotomous outcomes (e.g. adverse events, or time-to-event data if it is not possible to use a hazard ratio), we will use the risk ratio.
- For continuous outcomes, we will use the mean difference between treatment arms if all trials measured the outcome on the same scale, otherwise standardised mean differences will be used.

Data synthesis

- For any dichotomous outcomes, the risk ratio will be calculated for each study and these will then be pooled.
- For continuous outcomes, the mean differences (or standardised mean differences) between the treatment arms at the end of follow-up will be pooled".

We did not produce a funnel plot to assess the potential for small study effects, since there were only two studies in any of the meta-analyses that assessed OS in women with residual disease of different thresholds compared to women with microscopic disease. The following paragraph on reporting biases was removed:

"Assessment of reporting biases

Funnel plots corresponding to meta-analysis of the primary outcome will be examined to assess the potential for small study effects. When there is evidence of small-study effects, publication bias will be considered as only one of a number of possible explanations. If these plots suggest that treatment effects may not be sampled from a symmetric distribution, as assumed by the random effects model, sensitivity analyses will be performed using fixed effects models".

"Subgroup analysis and investigation of heterogeneity

Sub-group analyses will be performed, grouping the trials by:

- Disease free interval
- Optimal cytoreduction achieved at the primary treatment

Factors such as age, stage, length of follow-up, will be considered in interpretation of any heterogeneity".

The review was restricted to studies that were at high risk of bias so we did not carry out sensitivity analyses. We had specified the following in the protocol:

"Sensitivity analysis

Sensitivity analyses will be performed excluding studies at high risk of bias".

INDEX TERMS

Medical Subject Headings (MeSH)

Antineoplastic Agents [therapeutic use]; Carcinoma, Ovarian Epithelial; Neoplasm Recurrence, Local [drug therapy] [mortality] [pathology] [*surgery]; Neoplasm, Residual; Neoplasms, Glandular and Epithelial [drug therapy] [mortality] [pathology] [*surgery]; Ovarian Neoplasms [drug therapy] [mortality] [pathology] [*surgery]; Tumor Burden

MeSH check words

Adult; Female; Humans